Agilent Receives a Hold from UBS

By Austin Angelo

UBS analyst Jon Groberg reiterated a Hold rating on Agilent (NYSE: A) yesterday and set a price target of $48. The company’s shares closed yesterday at $45.40.

According to TipRanks.com, Groberg is a 4-star analyst with an average return of 9.3% and a 74.0% success rate. Groberg covers the Healthcare sector, focusing on stocks such as Quintiles Transnational, Charles River Labs , and Foundation Medicine.

Agilent has an analyst consensus of Moderate Buy, with a price target consensus of $50.14.

Based on Agilent’s latest earnings report for the quarter ending July 31, the company posted quarterly revenue of $1.04 billion and quarterly net profit of $124 million. In comparison, last year the company earned revenue of $1.04 billion and had a net profit of $140 million.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. Last month, Patrick Kaltenbach, the SVP of A sold 2,000 shares for a total of $94,600.

Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics, diagnostics and genomics industries. It operates through the following segments: Life Sciences, Chemical Analysis, Diagnostics & Genomics and Electronic Measurement. The Life Sciences segment provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. The Chemical Analysis segment manufactures gas chromatography mass spectrometry systems, inductively coupled plasma mass spectrometry instruments, atomic absorption instruments, inductively coupled plasma optical emission spectrometry instruments, molecular spectroscopy instruments, vacuum pumps and measurement technologies supports and services. The Diagnostics & Genomics segment provides solutions that include reagents, instruments, software and consumables that enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. The Electronic Measurement segment provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and microscopy products. The company was founded in 1999 and is headquartered in Santa Clara, CA.